PACTR202301768862135尚未招募2 期
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •APOL1 genotype of G1/G1, G2/G2, or G1/G2
- •Proteinuric kidney disease
排除标准
- •Key Exclusion Criteria:
- •Solid organ or bone marrow transplant
- •Uncontrolled hypertension
- •Diagnosis of diabetes mellitus
- •Known underlying cause of kidney disease including but not limited to sickle cell disease
- •Other protocol defined Inclusion/Exclusion criteria apply.
研究者
相似试验
已完成
3 期
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn*s Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapyinflammatory bowel disease10017969Crohn's DiseaseNL-OMON45775Takeda9
进行中（未招募）
1 期
A Phase 3 Study to Evaluate the Safety and Efficacy of BMN 111 in Children with AchondroplasiaachondroplasiaMedDRA version: 20.0 Level: LLT Classification code 10000452 Term: Achondroplasia System Organ Class: 100000004850EUCTR2015-003836-11-GBBioMarin Pharmaceutical Inc.110
进行中（未招募）
1 期
A Study in Patients with Chronic Cluster HeadacheEUCTR2014-005429-11-BEEli Lilly and Company162
进行中（未招募）
1 期
A study in Patients with Episodic Cluster HeadacheMedDRA version: 19.0Level: LLTClassification code 10009698Term: Cluster headachesSystem Organ Class: 100000004852EUCTR2015-000149-22-NLEli Lilly and Company162
进行中（未招募）
1 期
Phase 3 Study of Epacadostat and Pembrolizumab in MelanomaMelanomaEUCTR2015-004991-31-SEIncyte Corporation706